- 1. Advances in Cardiovascular Toxicology
- 2. Pathobiology of Myocardial Ischemic Injury—Implications for Pharmacology and Toxicology
- 3. Nonclinical Safety Assessment of the Cardiovascular Toxicity of Drugs and Combination Medical Devices
- 4. Novel Approaches in the Evaluation of Cardiovascular Toxicity
- 5. Nonhuman Primate Models for Cardiovascular Research
- 6. Cardiovascular Toxicity of Antimicrobials
- 7. Cardiotoxicity of Anthracyclines and Other Antineoplastic Agents
- 8. Pathogenesis of Catecholamine-Induced Cardiomyopathy
- 9. Adverse Cardiovascular Effects of Centrally Acting Psychiatric Medications
- 10. Adverse Effects of Drugs on Electrophysiological Properties of the Heart
- 11. Cardiovascular Effects of Steroidal Agents
- 12. Cardiotoxicity of Industrial Chemicals and Environmental Pollution
- 13. Passive Smoking Causes Heart Disease
- 14. Vascular Toxicology: A Cellular and Molecular Perspective
- 15. Pathobiology of the Vascular Response to Percutaneous Coronary Intervention and Drug-Eluting Stents
- 16. The Arterial Media as a Target of Structural and Functional Injury by Chemicals
- Index
- Daniel Acosta, Jr., University of Cincinnati, Cincinnati, Ohio, USA
DANIEL ACOSTA, JR. is Dean of the College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. He is the first and only Hispanic dean at the University of Cincinnati and the only Hispanic dean of pharmacy among the research-intensive colleges of pharmacy in the United States. Dr. Acosta is active in numerous scientific and professional organizations, serves on several editorial boards of toxicology and in vitro journals, and has been appointed to a number of government and private committees. He has been the recipient of many awards and honors, including the Burroughs Welcome Toxicology Scholar Award, the Foundation Award in Excellence from the Pharmaceutical Research and Manufacturers of America Foundation, and several endowed professorships from the University of Texas, where he taught for 22 years. He was also elected president of the Society of Toxicology from 2000 to 2001 and was recently honored with the 2005 Society of Toxicology’s Enhancement of Animal Welfare Award. At the University of Cincinnati, he has been a driving force in implementing a new entry-level Pharm.D. program, in addition to several new degree programs, including one of the first national masters programs in drug development.
